An Open-Label Study of the Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders
Latest Information Update: 11 Nov 2024
At a glance
- Drugs Divozilimab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Acronyms AQUARELLE
- Sponsors Biocad
Most Recent Events
- 07 Nov 2024 Planned End Date changed from 1 Apr 2025 to 1 Sep 2026.
- 07 Nov 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Jan 2025.
- 07 Nov 2024 Status changed from recruiting to active, no longer recruiting.